Moving radiotherapy forward - CHART-ED
Case Study
Continuous Hyperfractionated Accelerated RadioTherapy (CHART) remains an important radiotherapy study. Dr Matthew Hatton from Sheffield ECMC lead the multi-site phase I trial CHART-ED to assess the feasibility of radiotherapy dose-escalation for treating patients with inoperable stage III non-small cell lung cancer (NSCLC). The trial recruited patients who presented with locally...
Use of IT and social media by health professionals - 21 May 2015
Resource
Agenda Dynamic consent - Harriet Teare, Oxford CRUK's Citizen Science Programme - Rupesh Vyas, Cancer Research UK Use of social media: General overview - Kimberley Freeman, UCL Use of social media: Research Nurse perspective (video) - Claire Gibbs, James Paget TED talks - Joyjit Sarkar, TEDx Brum Use of blogs...
Adaptive trial design for early phase trials - 21 May 2015
Resource
Agenda Why not use 3+3 - Dr Thomas Jaki and Dr Lisa Hampson, Lancaster University Model based dose-finding - Dr Thomas Jaki and Dr Lisa Hampson, Lancaster University Bibliography
Future direction and plans for the ECMC QATS Network Group - 21 May 2015
Resource
Agenda Summary from the QATS meeting on 25 February - Karen Swales, ICR ECMC QATS Network Group: next steps Ways of working for the QATS Network Group - Alex MacLellan, Edinburgh
ECMC Annual Network meeting - 21 May 2015: Presentations
Basic page
The ECMC Annual Network meeting took place on Thursday 21 May 2015; below are the agendas and presentations from the meeting.
ECMC Patient Experience Survey 2015
Resource
The steering committee of the ECMC Research Nurse Network Group agreed that it was important to try to gain an understanding of the experience of patients participating in early phase trials. A survey was undertaken in March 2015 to determine patient satisfaction. Below are a number of documents relating to...
ECMC Joint Steering Committee Members
Basic page
Core members Extended members Jeff Evans, Glasgow ECMC Duncan Jodrell, Cambridge ECMC Michael Seckl, Imperial ECMC Christian Ottensmeier, Southampton ECMC Timothy Yap, ICR ECMC Emma Dean, Manchester ECMC James Larkin, NIHR Early phase lead, Royal Marsden Susan Short, Leeds ECMC Rebecca Kristeleit, UCL ECMC Louis Chesler, ICR ECMC Richard Baird,...
RaDCom
Basic page
Radiotherapy-Drug Combinations Consortium (RaDCom) The Radiotherapy-Drug Combinations Consortium (RaDCom) was established by CTRad and the Cancer Research UK (CRUK) Centre for Drug Development (CDD) in 2013. RaDCom is a collaborative network of UK-based laboratories working in partnership with industry, CRUK and other funding bodies; it seeks to work with UK-based...
CRUK Centre for Drug Development
Basic page
At the Cancer Research UK Centre for Drug Development (CDD) we translate today’s science into tomorrow’s medicine. The academic, pharmaceutical and biotechnology sectors across the globe trust us to realise the full potential of their research. This is why we are the partner of choice for early phase cancer drug...
ECMC History and Vision
Basic page
History Launched in 2007, the network is funded by Cancer Research UK, the Little Princess Trust, the National Institute for Health Research in England, and the Health Departments for Scotland, Wales, and Northern Ireland. Since then about £150 million of ECMC funding has been supporting staff members across the UK...